• DNDi logo
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Global Headquarters
      • DNDi DRC
      • DNDi East Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
DNDi logo
  • DNDi logo
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Global Headquarters
      • DNDi DRC
      • DNDi East Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Our people

Our governance

Home > Our people

Our governance

 

Board of Directors

DNDi is governed by a Board of Directors that approves project selection and sets policies governing intellectual property, financial control, and ethics.

The Board consists of representatives from six of DNDi’s founding partners, a patient advocate who represents the communities we serve, and up to eight other members with additional required skills, knowledge, or experience.

A representative of the World Health Organization (as represented by UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases) and the Chair of the DNDi Scientific Advisory Committee are permanent observers. The DNDi Executive Director is a permanent invitee.

In addition, our regional offices are governed by Boards of Directors.

Loading...
Dr Marie-Paule Kieny
Marie-Paule Kieny

DNDi Board Chair

Institut national de la santé et de la recherche médicale (Inserm), France
Paul Herrling
Paul Herrling

DNDi Board Secretary

Formerly Novartis International, Switzerland
FredericVallat2019
Frédéric Vallat

DNDi Board Treasurer

Ville de Genève, Switzerland
AlwynMwinga2019
Alwyn Mwinga

DNDi Board Patient representative

CEO ZAMBART Project, Zambia DNDi Board Patient representative
NoorHishamAbdullah2019
Noor Hisham Abdullah
Director General of Health, Ministry of Health, Malaysia
JorgeBermudez
Jorge Bermudez
Head of Department of Policies for Pharmaceutical Drugs and Assistance (NAF) of the National School of Public Health (Ensp/Fiocruz)
BalramBhargava2019
Balram Bhargava
Secretary, Department of Health Research, Ministry of Health & Family Welfare, Government of India and Director General, Indian Council of Medical Research
Chris Bird
Chris Bird
General Counsel and Company Secretary, Wellcome
Christos Christou
Christos Christou
International President, Médecins Sans Frontières
StewartCole2019
Stewart Cole
President, Institut Pasteur, France
Silvia Gold
Silvia Gold
President, Mundo Sano Foundation
SuerieMoon2019
Suerie Moon
Co-Director, Global Health Centre, Graduate Institute and Adjunct Lecturer, Harvard T.H. Chan School of Public Health
BernardOgutu2019
Bernhards Ogutu
Chief Research Officer, KEMRI
Kristine Husoy Onarheim
Kristine Husøy Onarheim
Bergen Centre for Ethics and Priority Setting, University of Bergen, Norway
John Reeder
John Reeder

DNDi Board Permanent Observer

Director, WHO-TDR
BernardPecoul2019
Bernard Pécoul
Executive Director, DNDi and DNDi Board Permanent Invitee
Nick White
Nick White

DNDi Scientific Advisory Committee Chair and DNDi Board Permanent Invitee

Professor of Tropical Medicine, Mahidol University, Thailand and Oxford University, UK


Scientific Advisory Committee

The DNDi Scientific Advisory Committee provides independent and exclusively evidence-driven recommendations to the Board of Directors on matters related to research and development and choice of projects.

The Committee is composed of prominent scientists with drug discovery and development expertise, as well as medical and public health experts with disease-specific expertise or expertise with specific neglected populations
(e.g. children).

The Committee operates independently of the Board of Directors and the Executive Team. The Board of Directors approves the selection of Committee members.

Loading...
Nick White
Nick White

DNDi Scientific Advisory Committee Chair and DNDi Board Permanent Invitee

Professor of Tropical Medicine, Mahidol University, Thailand and Oxford University, UK
Rashmi Barbhaiya
Rashmi Barbhaiya
Founder & former CEO and Managing Director Advinus Therapeutics, India
Kirana Bhatt
Kirana Bhatt
Professor of Medicine, University of Nairobi, Kenya
Pierre-Etionne Bost
Pierre-Etienne Bost
Formerly Institut Pasteur, France
Pierre Buffet
Pierre Buffet
Medical Director, Institut Pasteur, France
Joseph Camardo
Joseph Camardo
Chief Medical Officer, ADC Therapeutics
Andre Daher
Andre Daher
Head of Clinical Research, Farmanguinhos/FIOCRUZ, Brazil
Valérie Faillat
Valérie Faillat
Head of the Sanofi Espoir Foundation
Lisa Frigati
Lisa Frigati
Senior Registrar, Tygerberg Hospital, South Africa
Dale Kempf
Dale Kempf
Distinguished Research Fellow and Director of Neglected Diseases Research, AbbVie, USA
Steve King
Steve King
Former VP, Development Sciences, AbbVie
Lucy Lum Chai See
Lucy Lum Chai See
University of Malaya Medical Center, Kuala Lumpur
Subir Kumar Maulik
Subir Kumar Maulik
Emeritus Scientist, Indian Council of Medical Research, India
Tomo Nozaki
Tomo Nozaki
Professor at the Graduate School of Medicine, The University of Tokyo, & President, Japanese Society of Parasitology
Muhammad Radzi Abu Hassan
Muhammad Radzi Abu Hassan
Head of Internal Medicine Services, Consultant Physician and Gastroenterologist, Ministry of Health Malaysia
Yves Ribeill
Yves J. Ribeill
Founder and former CEO of Scynexis, Inc., Partner at Argobio
Koert Ritmeijer
Koert Ritmeijer
Coordinator Research, Médecins Sans Frontières – Operational Centre Amsterdam
Nilanthi de Silva
Nilanthi de Silva
Vice-Chancellor and Senior Professor of Parasitology, University of Kelaniya, Sri Lanka
MurielVray2019
Muriel Vray
Epidemiologist, Institut Pasteur, France

DNDi Access Committee

The DNDi Access Committee provides advice to the DNDi leadership team on the quality and completeness of access to medicines plans to ensure that the treatments developed by DNDi and its partners reach the neglected populations that need them.

To ensure that all potential issues that can impact patients’ access to treatments are considered, the Committee is composed of experts with a wide variety of qualifications and expertise, including in the fields of anthropology, health economics, supply chain management, industrial affairs, public health. Created in 2021, the Committee is composed of fifteen members chosen based on their experience and expertise in these and other fields related to access to treatments.

Loading...
Carolina Batista
Head of Global Health Affairs, Baraka Impact Finance
Martin Bernhardt
Interim Director, Access Accelerated
Henk den Besten
Founder, CoachMan Consultancy
François Bompart
Access Committee Chair, DNDi
Jean-Marc Bouchez
Fosun Pharma Group
Jayasree K. Iyer
CEO, Access to Medicine Foundation
George Jagoe
Access and Product Management, Medicines for Malaria Venture (MMV)
Giten Khwairakpam
Community and Policy Program Manager, TREAT Asia, amfAR
Lenore Manderson
Distinguished Professor of Public Health and Medical Anthropology, University of the Witwatersrand
Dorothy Mbori-Ngacha
Senior HIV Specialist on EMTCT and Paediatric HIV, UNICEF
Kenneth Munge Kabubei
Kenya Country Office, World Bank
Carmen Pérez Casas
Senior Technical Manager, Strategy, Unitaid
Elisa Sicuri
ISGlobal, University of Barcelona, London School of Economics and Political Science
Tracy Swan
Independent Consultant, Access to Medicines/HIV, TB, HCV, and COVID-19
Veronika J. Wirtz
Professor, Boston University School of Public Health

Connect and share

Follow us on social media to stay updated and help us share the stories of neglected patients.  

Twitter
Facebook
Instagram
Youtube
Linkedin
EN ESPAÑOL
EM PORTUGUÊS
DNDi logo
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License   
We use cookies to track our audience and improve our content. By continuing to browse our website, you are agreeing to our use of cookies.CLOSECOOKIE POLICY